Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price, Quote & AI Analysis

Live BDTX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Black Diamond Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Black Diamond Therapeutics, Inc. Common Stock (BDTX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

BDTX
Black Diamond Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
0.000000
High
0.000000
Low
0.000000
Volume
0
VWAP
-
Market Cap
$141,867,533.37
52W Range
$1.20 - $4.94
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 4, 2026 Q4
After Hours
EPS Estimate: $-0.19
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Black Diamond Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Black Diamond Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Company Details
Market Cap
$141.35M
Shares Outstanding
56,974,914
Weighted Shares Outstanding
56,974,913
CEO
Mark A. Velleca
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142
Employees
54
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Black Diamond Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...